---
schema_version: "secwatch.filing_event.v1"
accession: "0001674930-26-000012"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:31:46.132530+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash

## Summary
- Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.
- StrataDx acquired for ~$13.5M cash; Bako Diagnostics assets acquired for ~$43.4M cash.
- Acquisition includes lease assignment for 29,099 sq ft lab/office in Alpharetta, GA through July 2032.
- Advisors: Piper Sandler and Mintz Levin for Fulgent; EV Health Partners and Latham & Watkins for sellers.
- Transaction originally announced Dec 22, 2025; closed March 17, 2026.

## SEC filing metadata
- accession: 0001674930-26-000012
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000012/0001674930-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000012/flgt-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001674930-26-000012
- JSON: https://secwatch.observer/filing/0001674930-26-000012.json
- Plain text: https://secwatch.observer/filing/0001674930-26-000012.txt

## Source-grounded claims
- claim_id: 5230f85c2a906e0c9740474d9bdd304304082dbf
  claim: Fulgent Genetics, Inc. completed an acquisition involving Inform Diagnostics, Inc. (closed 2026-03-17).
  evidence_excerpt: On March 17, 2026, the transactions contemplated by the PSA were completed (the "PSA Closing").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000012/0001674930-26-000012-index.htm
- claim_id: 64368db49e0509e52482fc6d7f8e7068237eba1e
  claim: Fulgent Genetics, Inc. completed an acquisition involving Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting (closed 2026-03-17).
  evidence_excerpt: On March 17, 2026, the transactions contemplated by the APA were completed (the "APA Closing").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674930/000167493026000012/0001674930-26-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.